JP Morgan Chase
FDMT icon

JP Morgan Chase’s 4D Molecular Therapeutics FDMT Stock Holding History

JP Morgan Chase’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,800
Closed -$77K – 7531
2023
Q4 		$77K Buy
+3,800
New +$50K ﹤0.01% 5849

Other funds holding FDMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase's FDMT Position: Q2 2026 in Review

JP Morgan Chase reduced its 4D Molecular Therapeutics (FDMT) stake by 3.3% in Q2 2026, selling an estimated $132K and leaving 402,137 shares worth $5.18M. The position accounts for ﹤0.01% of the portfolio, ranked #3417.

JP Morgan Chase first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $12.8M in Q1 2024. 96 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • JP Morgan Chase held 402,137 shares of 4D Molecular Therapeutics worth $5.18M as of Q2 2026.
  • JP Morgan Chase sold 13,518 4D Molecular Therapeutics shares in Q2 2026, an estimated $132K.
  • 4D Molecular Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #3417 holding.
  • JP Morgan Chase first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • JP Morgan Chase's 4D Molecular Therapeutics position peaked at $12.8M in Q1 2024.
  • 96 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.